One of the most influential and accomplished figures in the field of cancer immunotherapy has returned to his Western New York roots to take on leadership roles in both research and clinical care at Roswell Park Comprehensive Cancer Center.
Those diagnosed with von Hippel-Lindau disease have a resource for that complete and coordinated care in Roswell Park Comprehensive Cancer Center, which was recently named a VHL Clinical Care Center by the VHL Alliance.
A unique two-drug immunotherapy combination first evaluated at Roswell Park Comprehensive Cancer Center as an approach for treating some cancers will soon be available to cancer patients with COVID-19 through a clinical trial at Roswell Park.
A team led by Pawel Kalinski, MD, PhD, of Roswell Park Comprehensive Cancer Center has earned a five-year, $14.54 million award from the National Cancer Institute to expand a promising immunotherapy platform.
In a pair of new studies, researchers from Roswell Park Comprehensive Cancer Center outline strategies for overcoming pancreatic cancer’s resistance to treatment through approaches that exploit this cancer’s reliance on uncontrolled, or deregulated, cell proliferation.